Reevaluating the FDA's warning against the use of probiotics in preterm neonates: A societal statement by ESPGHAN and EFCNI

Chris H.P. van den Akker, Nicholas D. Embleton, Alexandre Lapillonne, Walter A. Mihatsch, Silva Salvatore, Roberto B. Canani, Ener C. Dinleyici, Magnus Domellöf, Alfredo Guarino, Pedro Gutiérrez-Castrellón, Iva Hojsak, Flavia Indrio, Alexis Mosca, Rok Orel, Johannes (Hans) B. van Goudoever, Zvi Weizman, Silke Mader, Luc J.I. Zimmermann, Raanan Shamir, Yvan VandenplasHania Szajewska

    Research output: Contribution to journalArticlepeer-review

    1 Scopus citations

    Abstract

    The recent advisory issued by the United States Food and Drug Administration, cautioning against the routine administration of probiotics in preterm neonates, has sparked a lively debate within the scientific community. This commentary presents a perspective from members of the Special Interest Group on Gut Microbiota and Modifications within the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and other authors who contributed to the ESPGHAN position paper on probiotics for preterm infants, as well as representatives from the European Foundation for the Care of Newborn Infants. We advocate for a more nuanced and supportive approach to the use of certain probiotics in this vulnerable population, balancing the demonstrated benefits and risks.

    Original languageEnglish
    JournalJournal of Pediatric Gastroenterology and Nutrition
    DOIs
    StateAccepted/In press - 1 Jan 2024

    Keywords

    • live biotherapeutic product
    • necrotizing enterocolitis
    • premature infants
    • probiotic drug
    • probiotic sepsis

    ASJC Scopus subject areas

    • Gastroenterology
    • Pediatrics, Perinatology, and Child Health

    Fingerprint

    Dive into the research topics of 'Reevaluating the FDA's warning against the use of probiotics in preterm neonates: A societal statement by ESPGHAN and EFCNI'. Together they form a unique fingerprint.

    Cite this